During the 2025 Annual Meeting of the China Development Forum, Pascal Soriot, the Global CEO of AstraZeneca, underscored China's pivotal role in the realm of medical innovation. He noted that the approval timeline for clinical trials in China has been dramatically reduced, thereby expediting the commercialization of new technologies. Additionally, Soriot highlighted the transformative impact of AI technology on medical innovation and therapeutic advancements. Looking ahead, he emphasized the necessity of bolstering fundamental scientific research and fostering an innovative ecosystem. Echoing the belief that science transcends borders, Soriot also stressed the crucial importance of maintaining the stability and sustainable growth of the industrial chain.
